News Releases

GLENN ALLEN, Va., Jul 11, 2006 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ:INSM) today announced that Philip J. Young, Chief Business Officer of Insmed, will present a corporate overview on Wednesday, July 12 at 1:35 PM ET during the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference taking place in New York. Investors may access a live audio webcast of the presentation via http://www.wsw.com/webcast/ceut4/insm/. 

About Insmed 

Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit http://www.insmed.com. 

Forward Looking Statements 

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.